IBA Partners with MD Anderson to Assess Clinical and Economic Value of Proton Therapy
On Wednesday, IBA signed a sponsored research agreement with the University of Texas MD Anderson Cancer Center, aiming to generate robust clinical and economic evidence on the value of proton therapy compared to other cancer treatment modalities.
A Partnership to Evaluate the Economic Viability of Proton Therapy
The agreement connects IBA with two researchers from UT MD Anderson: Dr. Matthew Ning, Assistant Professor in Radiation Oncology, and Dr. Iakovos Toumazis, Assistant Professor in Health Services Research. The collaboration will focus on a series of projects aimed at evaluating the cost-effectiveness of proton therapy across various types of cancers, considering clinical outcomes, toxicity reduction, and broader economic impacts.
Researchers will examine the cost-effectiveness of proton therapy compared to alternative treatments, analyze direct and indirect costs from the perspectives of payers, patients, and society, and assess value variations across patient populations and oncological indications.
Precision Radiotherapy and Reduction of Long-Term Side Effects
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Proton therapy is one of the most advanced forms of radiotherapy, capable of delivering a highly precise radiation dose to the tumor while minimizing exposure to surrounding healthy tissues. This precision helps to reduce side effects and long-term toxicity, which are likely to be significant drivers of clinical value and overall health costs.
As health systems and payers increasingly prioritize value-based care, having robust evidence on clinical outcomes, toxicity reduction, and the total cost of care is essential for informing therapeutic decisions, reimbursement discussions, and patient access to treatments.
Improved Access and Responsible Resource Allocation
Olivier Legrain, CEO of IBA, stated: 'Generating high-quality evidence on the clinical and economic value of proton therapy is crucial for supporting informed decision-making, improving patient access, and helping health systems allocate resources responsibly. We are proud to collaborate with these talented scientists from UT MD Anderson on such relevant research.'
The agreement is part of IBA's broader strategy to strengthen its positioning in proton therapy solutions.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 323,7 millions d'euros
Quarterly revenue: 323,7 millions d'euros
EBITDA: 21,8 millions d'euros
EBITDA margin: 8,2 %
Net income: 9,3 millions d'euros
81 millions d'euros
Guidance from the release
Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées, reflétant la confiance du Groupe dans ses perspectives pour l'ensemble de l'année.
Risks mentioned
Surcapacité persistante sur le marché d'Industrial Solutions malgré un pipeline actif.
Retards temporaires de facturation liés à la migration ERP qui ont impacté la position financière nette.
Dosimetry reste sous pression malgré les mesures de réduction des coûts.
Opportunities identified
Forte dynamique commerciale en Proton Therapy avec cinq salles vendues et cinq prises de commandes de plus de €148 millions au S1.
PanTera a obtenu la qualification de fournisseur c-GMP d'actinium-225 et extension de collaboration avec TerraPower Isotopes pour tripler la capacité de production en Belgique.
Amélioration continue de la rentabilité : marge brute passée de 29,5% à 33,7% et EBITDA ajusté en croissance de 63%.
Outlook / guidance
Management commentary: Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées à au moins € 32 millions
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
